Table 2. Primary and Ranked Secondary End Points.

End point	Time point	Dupilumab, 300 mg (n = 331)	Upadacitinib, 30 mg (n = 342)	Difference	P value
Primary end point
Achievement of EASI75a	Week 16	207 (62.6) [57.4 to 67.8]	248 (72.4) [67.6 to 77.2]	9.7	.007
Secondary end points in order of ranking
% Change from baseline in worst pruritus NRSb	Week 16	−49.6(2.0) [–53.5 to −45.7]	−67.8 (1.9) [–71.5 to −64.0]	−18.21	<.001
No.		239	252
Achievement of EASI100a	Week 16	26 (7.9) [5.0 to 10.8]	97 (28.4) [23.6to 33.2]	20.4	<.001
Achievement of EASI90a	Week 16	133 (40.3) [35.0 to 45.6]	211 (61.6) [56.4 to 66.8]	21.2	<.001
% Change from baseline in Worst Pruritus NRSb	Week 4	−32.4 (2.3) [–36.9 to −27.9]	−60.4 (2.2) [–64.7 to −56.1]	−28.0	<.001
No.		297	327
Achievement of EASI75a	Week 2	60 (18.2) [14.0 to 22.4]	152 (44.3) [39.1 to 49.6]	26.1	<.001
% Change from baseline in Worst Pruritus NRSb	Week 1	−8.9 (1.8) [–12.5 to −5.3]	−32.0 (1.8) [–35.4 to −28.5]	−23.0	<.001
No.		314	331
Worst Pruritus NRS improvement ≥4 pointsa,c	Week 16	117 (36.4) [31.1 to 41.6]	188 (56.1) [50.8 to 61.5]	19.8	<.001
No.	NA	323	334	NA	NA

Abbreviations: EASI75, 75% improvement in the Eczema Area and Severity Index; NA, not applicable; NRS, Numerical Rating Scale.

^a No. (%) [95% CI].

^b Least-squares mean (SE) [95% CI].

^c Analyzed for patients with Worst Pruritus NRS of 4 points or higher at baseline.